Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atorvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 10/20 | 0.97 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.97 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.97 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.97 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.97 |
| ▸ | RHOC | P08134 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.97 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.97 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.84 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.84 |
| ▸ | PDE6D | O43924 | 3/20 | 0.75 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atorvastatin SCHEMBL618614 | 1.00 | HMGCR (0.97) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL19469652 | 1.00 | HMGCR (0.97) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL26978250 | 1.00 | HMGCR (0.97) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL14968747 | 1.00 | HMGCR (0.97) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL5451363 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL524785 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL28270206 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL7037657 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL1402150 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL28457 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14280 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20250332254-A1 | METHODS FOR TREATING PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA | REGENERON PHARMA (US) | 2025-10-30 | — | — | US | claimed |
| US-20250303156-A1 | CONCOMITANT TREATMENT OF TTFIELDS AND HMG-CO A REDUCTASE INHIBITORS | NOVOCURE GMBH (CH) | 2025-10-02 | — | — | US | claimed |
| WO-2025202988-A1 | CONCOMITANT TREATMENT WITH TTFIELDS AND HGM-COA REDUCTASE INHIBITORS | NOVOCURE GMBH (CH) | 2025-10-02 | — | — | WO | claimed |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | claimed |
| US-20250264469-A1 | METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER | 2025-08-21 | — | — | US | claimed |
| US-20250179219-A1 | CYCLODEXTRIN DIMERS, COMPOSITIONS THEREOF, AND USES THEREOF | CYCLARITY THERAPEUTICS INC (US) | 2025-06-05 | — | — | US | claimed |
| US-20250057803-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION | TOPELIA AUST LTD ACN 652 771 670 (AU) | 2025-02-20 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-1286702-A2 | HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS | St. Elizabeth's Medical Center of Boston, Inc. (US) | 2003-03-05 | — | — | EP | claimed |
| WO-2003000840-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2003-01-03 | — | — | WO | claimed |
| US-20020155173-A1 | Nitric oxide donors for inducing neurogenesis | HENRY FORD HEALTH SYSTEMS | 2002-10-24 | — | — | US | claimed |
| US-20020099291-A1 | Systems and methods for assessing vascular effects of a treatment | NEW HEALTH SCIENCES, INC. | 2002-07-25 | — | — | US | claimed |
| US-20020058026-A1 | HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10 | HAMMERLY MILTON (US) | 2002-05-16 | — | — | US | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| WO-2002026118-A2 | SYSTEMS AND METHODS FOR ASSESSING VASCULAR EFFECTS OF A TREATMENT | NEW HEALTH SCIENCES, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| US-20020004521-A1 | Use of HMG-COA reductase inhibitors to prevent and treat BPH | WEISMAN KENNETH (US) | 2002-01-10 | — | — | US | claimed |
| WO-2001093806-A2 | HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS | ST. ELIZABETH'S MEDICAL CENTER OF BOSTON, INC. (US) | 2001-12-13 | — | — | WO | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |